Processa Pharmaceuticals : Ngc-Cap Phase 1B Trial Demonstrated a Favorable Safety Profile With Preliminary Anti-Tumor Activity
Processa Pharmaceuticals: Ngc-Cap第10億試驗展示了良好的安全性和初步的抗腫瘤活性
Processa Pharmaceuticals : Ngc-Cap Phase 1B Trial Demonstrated a Favorable Safety Profile With Preliminary Anti-Tumor Activity
Processa Pharmaceuticals: Ngc-Cap第10億試驗展示了良好的安全性和初步的抗腫瘤活性
譯文內容由第三人軟體翻譯。